AN-788

AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder. It was also under development for anxiety disorders, but development for this indication was discontinued. The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI). As of April 2016, it is in phase I clinical trials for major depressive disorder.

AN-788

AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder. It was also under development for anxiety disorders, but development for this indication was discontinued. The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI). As of April 2016, it is in phase I clinical trials for major depressive disorder.